8-K: The Joint Corp. Reports Mixed Q3 2024 Results Amid Refranchising Efforts

The Joint Corp. announced a 2% revenue increase to $30.2 million for Q3 2024, alongside a net loss of $3.2 million, as it continues its refranchising strategy.

Summary

• The Joint Corp. reported a 2% increase in revenue to $30.2 million for the third quarter of 2024, compared to $29.5 million in the same period of 2023.
• The company experienced a net loss of $3.2 million in Q3 2024, which includes a $3.8 million loss on disposition or impairment, compared to a net loss of $716,000 in Q3 2023.
• Adjusted EBITDA for Q3 2024 was $2.4 million, down from $2.9 million in Q3 2023.
• System-wide sales increased by 8% to $129.3 million, while system-wide comparable sales grew by 4%.
• The company sold 7 franchise licenses in Q3 2024, the same as Q2 2024, but down from 12 in Q3 2023.
• The total clinic count reached 963, with 838 franchised and 125 company-owned or managed clinics.
• For the first nine months of 2024, revenue was $90.2 million, compared to $87.1 million in the same period of 2023, with a net loss of $5.8 million.
• The company has revised its 2024 guidance, expecting system-wide sales between $525 million and $535 million, and system-wide comp sales between 3% and 4%.

Sentiment

Score: 4

Explanation: The sentiment is mixed. While there is revenue growth and a focus on strategic initiatives, the significant net loss, decreased EBITDA, and downward revision of guidance raise concerns. The refranchising strategy introduces both opportunities and risks.

Positives

• The company experienced a 2% increase in revenue to $30.2 million in Q3 2024.
• System-wide sales increased by 8% to $129.3 million.
• System-wide comp sales grew by 4%.
• The company has a strong liquidity position with $20.7 million in unrestricted cash and access to a $20 million line of credit.
• The company is focused on new patient acquisition through increased awareness campaigns and digital marketing.

Negatives

• The company reported a net loss of $3.2 million in Q3 2024, a significant increase from the $716,000 loss in Q3 2023.
• Adjusted EBITDA decreased to $2.4 million in Q3 2024 from $2.9 million in Q3 2023.
• The company experienced a $3.8 million loss on disposition or impairment in Q3 2024.
• Franchise license sales decreased to 7 in Q3 2024 from 12 in Q3 2023.
• The company has revised its 2024 guidance downwards for system-wide sales and new franchised clinic openings.

Risks

• The company faces challenges in recruiting qualified chiropractors and other personnel due to a nationwide labor shortage.
• Inflation has increased the company's costs and could negatively impact its business.
• The company's refranchising efforts may not proceed as planned.
• Short-selling strategies and negative opinions on the internet could drive down the market price of the company's stock.
• The company may fail to remediate future material weaknesses in its internal control over financial reporting.

Future Outlook

The company has revised its 2024 guidance, expecting system-wide sales between $525 million and $535 million, and system-wide comp sales between 3% and 4%. New franchised clinic openings are expected to be between 55 and 60.

Management Comments

• The Joint's long-term opportunities far exceed the near-term consumer headwinds, said President and Chief Executive Officer of The Joint Corp. Sanjiv Razdan.
• The board and I are committed to our refranchising efforts; elevating patient care; ensuring strong clinic economics; strengthening our people, capability and culture; and fueling innovation to drive growth and improve profitability.
• With the power behind The Joint franchise concept, our strategies to improve clinic economics, increase patient count, and drive growth will increase profitability and create shareholder value.
• I am confident we will emerge a stronger company.

Industry Context

The Joint Corp. operates in the chiropractic care industry, which is experiencing a growing demand for non-invasive pain management solutions. The company is a category leader with a significant number of clinics and a focus on a franchise model. The company is competing with other chiropractic clinics and healthcare providers.

Comparison to Industry Standards

• The Joint Corp.'s system-wide sales growth of 8% is a positive indicator, but the net loss and decrease in Adjusted EBITDA are concerning when compared to industry leaders.
• While specific competitor data is not provided, companies like Massage Envy and other franchise healthcare models could be used as benchmarks for comparison.
• The company's refranchising strategy is a unique approach, and its success will be crucial for future growth and profitability.
• The company's 4% system-wide comp sales growth is in line with industry averages, but the downward revision of guidance suggests potential challenges ahead.

Stakeholder Impact

• Shareholders may be concerned about the net loss and decreased profitability.
• Franchisees may be impacted by the refranchising efforts and changes in clinic operations.
• Employees may be affected by the company's cost-cutting measures and restructuring.
• Customers may experience changes in clinic locations and services due to the refranchising process.

Next Steps

• The company will continue its refranchising efforts.
• The company will focus on new patient acquisition through increased awareness campaigns and digital marketing.
• The company will host a conference call to discuss the results.

Key Dates

Keywords

chiropractic, franchise, refranchising, EBITDA, system-wide sales, clinic, revenue, net loss, financial results, healthcare